Inherited genetic testing for pancreatic cancer
What inherited (germline) genetic testing is, how it differs from tumour testing, who should ask about it, and what results mean for patients and families.
Inherited genetic testing — also called germline testing — looks for gene changes that may matter for your care and for your family.
If you have pancreatic ductal adenocarcinoma, ask your care team about germline testing even if no one else in your family has had pancreatic cancer. Eligibility and testing arrangements vary, so confirm them with your local service.
This guide is general information, not medical advice.
In brief
- Germline testing looks for gene changes present in the DNA you were born with. These changes can run in families.
- Some findings may help inform treatment discussions; many results do not change treatment.
- A finding may also have implications for blood relatives, who can be offered advice and testing of their own.
- No result removes all uncertainty: a test can only report on the genes and changes it examines.
What is inherited genetic testing?
Everyone’s DNA contains small differences. A few of them — called pathogenic variants — increase the risk of certain cancers. Germline testing examines DNA from a blood or saliva sample for these inherited changes.
A proportion of pancreatic cancers are associated with inherited pathogenic variants. Testing can identify some of these findings, including in people without an obvious family history. Panels commonly include genes such as BRCA1, BRCA2, PALB2, ATM, CDKN2A, and the mismatch repair genes associated with Lynch syndrome, among others.
How is it different from tumour biomarker testing?
The two tests answer different questions. Germline testing looks at the DNA you were born with, present in every cell. Tumour (somatic) biomarker testing looks at changes that developed inside the cancer itself. One is not a more complete version of the other; some people are offered both. See our guide to biomarker testing.
Who should ask about testing?
People diagnosed with pancreatic ductal adenocarcinoma are the main audience for this guide: inherited testing is widely recommended after this diagnosis, whatever your age and whether or not relatives have had cancer.
Not diagnosed, but concerned about family history?
If several close relatives have had pancreatic, breast, ovarian, colorectal, or related cancers — or a relative is known to carry an inherited variant — a referral to genetic counselling can help you understand your own risk and whether testing or surveillance applies to you. You do not need a cancer diagnosis to ask for that conversation.
What happens during testing?
Testing is usually arranged through your oncology team or a genetics service. Pathways differ: in some centres the cancer team orders the test directly (sometimes called mainstream testing); in others a genetics service manages it. The usual steps are a conversation about what the test can and cannot show, your consent, a blood or saliva sample, laboratory analysis, and a results appointment where the findings and next steps are explained. Ask the ordering service when results are expected, how you will receive them, and whom to contact if they are delayed.
What might the results mean?
| Result | What it means |
|---|---|
| Pathogenic or likely pathogenic variant | A finding considered harmful or likely harmful. What it implies depends on the gene and your circumstances; your team will explain what it means for treatment and for relatives. |
| No pathogenic variant identified | No harmful change was found within the scope of the test. This does not eliminate cancer risk — the test only covers certain genes and changes, and a negative result can mean different things depending on your family’s history. |
| Variant of uncertain significance (VUS) | A change was found, but there is not enough evidence to know whether it affects risk. A VUS is generally not used to change medical management; its interpretation may be updated as evidence develops. |
Could results affect treatment?
Some inherited findings may help inform treatment discussions. Whether a particular treatment is appropriate depends on the gene finding, the cancer’s stage, previous treatment, your health, and access criteria. Your oncology team can explain what applies to you. See treatment options for the wider picture.
What could results mean for relatives?
A pathogenic finding may have implications for blood relatives. A genetics professional can explain which relatives should consider testing and their likelihood of carrying the same variant, and relatives can usually be referred for advice through their own care teams.
Some people with an inherited finding or a strong family history may qualify for specialist pancreatic surveillance. Eligibility, starting age, and testing intervals depend on the gene, family history, and the local program — ask for an individualized assessment rather than following a general schedule.
Access, cost, and privacy in Canada
Testing after a pancreatic cancer diagnosis is publicly funded in many circumstances, but arrangements and eligibility criteria are set provincially and differ between programs. Your care team or genetics service can confirm what applies to you, and whether any cost is involved.
Canada’s Genetic Non-Discrimination Act prohibits requiring a genetic test, or the disclosure of test results, as a condition of providing goods or services or entering into a contract, including insurance. If you have individual insurance or employment questions, a genetics service can point you to advice for your situation.
Questions to ask your care team
- Has germline testing already been ordered for me?
- Who will explain my results, and when?
- What happens if my result is uncertain?
- Does a negative result rule out inherited risk in my family?
- How can my relatives obtain advice or testing?
- What should I do if testing is not available through my current service?
Related guides
- What is biomarker testing?
- What is pancreatic cancer?
- Testing in pancreatic cancer
- Treatment options
Sources
- BC Cancer Hereditary Cancer Program — Eligibility criteria
- U.S. National Cancer Institute — Genetic testing for inherited cancer risk: fact sheet
- BC Cancer Hereditary Cancer Program — BRCA2: cancer risks and management
- Government of Canada — Genetic Non-Discrimination Act
Last reviewed: October 24, 2026